Researchers: Merit Cudkowicz, MD, Robert H Brown, D.Phil, M.D. and Anthony J. Windebank, M.D.
Sponsor: Brainstorm-Cell Therapeutics
Study: A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS
Summary: This is a multi-center, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of autologous (self) transplantation of Neurotrophic factors-secreting Mesenchymal Stromal Cells (MSC-NTF, NurOwn™) in patients with ALS .
MSC-NTF cells are a novel cell-therapeutic approach which is expected to effectively deliver Neurotrophic factors, which are potent survival factors for neurons, directly to the site of damage.
Study Status: Phase 2, Active
Researcher: John A Kessler, MD
Sponsor: ViroMed Co.
Summary: The purpose of this study is to determine the safety and tolerability of intramuscular injections of VM202 at different injection sites in people with amyotrophic lateral sclerosis.
Study Status: Phase 1, Active
If you feel that your research should be listed on this page, please contact us at email@example.com